July 21st 2025
BioXcel Therapeutics has submitted an pre-sNDA meeting package for Igalmi's outpatient use, aiming to enhance treatment options for agitation in bipolar disorders and schizophrenia.
Cobenfy as Add-On Treatment for Schizophrenia Fails to Meet Primary Endpoint in Phase 3 ARISE Trial
April 22nd 2025Cobenfy as an adjunctive treatment to atypical antipsychotics did not reach the primary endpoint of the phase 3 ARISE trial, or a statistically significant difference compared with placebo with an atypical antipsychotic.
Read More
Examining a Case of Acute Late-Pregnancy Psychosis: How Best to Coordinate Care
Peripartum psychosis is considered a psychiatric emergency. Here is how an interdisciplinary team can provide the best care.
Read More